Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

result, our ability to respond to the comments raised by the FDA regarding our manufacturing process may exceed the timeframe we currently anticipate and we cannot assure that we will be capable of generating the data requested by the FDA in the timeframe we anticipate. In addition, the FDA may request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationConsolidated Statements of Operations:Three months endedTwelve months ended(in thousands, except per share data)

December 31,December 31,2011201020112010(unaudited)Revenue:Net product sales

$ 145,575$ 121,623$ 544,374$ 439,012Costs and Expenses:Cost of sales (excluding amortization of product rights)

19,68317,93479,97661,288Research and development

12,70710,46066,47739,613Selling, general and administrativ
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... forecasts of its potential revenue from new rodenticide research ... investors and analysts on July 22, 2014, Neogen,s CEO ... regarding this research. "It was my intent ... the potential of a new type of rodenticide, but ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... ... is a thermally stable, economical and high-performance solution for operations with both high and ... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ...
... in the September 24th issue of Nature , ... technology to explore the ancient history of India, the ... reveals that nearly all Indians carry genomic contributions from ... groups experienced periods of genetic isolation from each other ...
... , ANN ARBOR, Mich., Sept. 23 ... Research Edition version 4.2, a significant product upgrade for ... has been fully committed to supporting academic and non-profit ... features a completely redesigned user-interface, improved search and filter ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2New research reveals the ancestral populations of India and their relationships to modern groups 2New research reveals the ancestral populations of India and their relationships to modern groups 3Compendia Bioscience Announces the Release of Oncomine 4 Research Edition 2
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... sustains irreparable damage in the wake of a heart ... the cardiac muscle contains few stem cells, the tissue ... and cannot contract properly. In their search for ... exploring cardiac "patches" that could be transplanted into the ...
... The chemical is known as an "endocrine disruptor," a substance ... found in everything from plastic drink bottles to the linings ... for cash register receipts not to mention the urine ... BPA has been associated with the development of chronic diseases ...
... animal welfare concern and can cause great economic losses ... whole. A new website has been launched to help ... The website [ http://www.featherwel.org ] has been developed ... Veterinary Sciences to improve bird welfare through FeatherWel, a ...
Cached Biology News:A heart of gold 2BPA + chlorine = bad news 2New website will help farmers ensure hens maintain good feather cover 2
... Epithelial and endothelial cells-directed ... a RGD peptide-conjugated polyethylenimine which ... integrin-expressing epithelial and endothelial cells. ... in cell-cell and cell-matrix adhesion ...
... WinMelt software is used ... of any DNA sequence up ... in optimizing placement of primers ... detection by denaturing gradient gel ...
Request Info...
... To score SNPs, Polymorphic uses proven, ... standard in DNA analysis. We use high ... can be confirmed by sequencing in both ... provides sequence context information, further confirming the ...
Biology Products: